FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151251762> ?p ?o ?g. }

• W2151251762 abstract "The pathotropic targeting of therapeutic nanoparticles to cancerous lesions is an innovative concept that has recently been reduced to practice in clinical trials for the treatment of metastatic cancer. Previously, we reported that intravenous infusions of Rexin-G, a pathotropic nanoparticle (or vector) bearing a cyto-ablative construct, induced tumor regression, reduced tumor burden, and improved survival, while enhancing the overall quality-of-life of patients with otherwise intractable chemotherapy-resistant cancers. In this report, we describe the major histopathological and radiologic features that are characteristic of solid tumors under the destructive influences of Rexin-G administered as a single therapeutic agent. To further promote tumor eradication and enhance cancer survival, we explored the potential of an auxiliary gene transfer strategy, specifically intended to induce a localized cancer auto-immunization in addition to assisting in acute tumor destruction. This immunization strategy uses Rexin-G in combination with Reximmune-C, a tumor targeted expression vector bearing a granulocyte macrophage-colony stimulating factor (GM-CSF) gene. Intravenous infusions of Rexin-G were given first to induce apoptosis and necrosis in the metastatic tumor nodules, thus exposing tumor neo-antigens, followed by Reximmune-C infusions, intended to recruit immune cells discretely into the same compartments (or lesions). The intent of this two-step approach is to bring a complement of cells involved in humoral and cell-mediated immunity in close proximity to the immunizing tumor antigens in a concerted effort to assist in tumor eradication and to promote a cancer vaccination in situ. Herein, we also describe the distinctive histopathologic and immunocytochemical features of tumors in terminal cancer patients who received Rexin-G infusions in combination with Reximmune-C. In addition to documenting the first histological indications of clinical efficacy achieved by this novel personalized approach to cancer vaccination, we discuss new methods and strategies for advancing its therapeutic utility. Taken together with the clinical data, these histological studies serve as valuable landmarks for medical oncology, and as definitive benchmarks for the emerging field of cancer gene therapy." @default.
• W2151251762 created "2016-06-24" @default.
• W2151251762 creator A5004151056 @default.
• W2151251762 creator A5011097529 @default.
• W2151251762 creator A5011784951 @default.
• W2151251762 creator A5018623286 @default.
• W2151251762 creator A5038795251 @default.
• W2151251762 creator A5039804524 @default.
• W2151251762 creator A5049248934 @default.
• W2151251762 creator A5051179447 @default.
• W2151251762 creator A5075917649 @default.
• W2151251762 creator A5090309244 @default.
• W2151251762 date "2007-06-01" @default.
• W2151251762 modified "2023-10-12" @default.
• W2151251762 title "Le morte du tumour: Histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes" @default.
• W2151251762 doi "https://doi.org/10.3892/ijo.30.6.1297" @default.
• W2151251762 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17487349" @default.
• W2151251762 hasPublicationYear "2007" @default.
• W2151251762 type Work @default.
• W2151251762 sameAs 2151251762 @default.
• W2151251762 citedByCount "10" @default.
• W2151251762 countsByYear W21512517622015 @default.
• W2151251762 countsByYear W21512517622018 @default.
• W2151251762 countsByYear W21512517622021 @default.
• W2151251762 countsByYear W21512517622022 @default.
• W2151251762 crossrefType "journal-article" @default.
• W2151251762 hasAuthorship W2151251762A5004151056 @default.
• W2151251762 hasAuthorship W2151251762A5011097529 @default.
• W2151251762 hasAuthorship W2151251762A5011784951 @default.
• W2151251762 hasAuthorship W2151251762A5018623286 @default.
• W2151251762 hasAuthorship W2151251762A5038795251 @default.
• W2151251762 hasAuthorship W2151251762A5039804524 @default.
• W2151251762 hasAuthorship W2151251762A5049248934 @default.
• W2151251762 hasAuthorship W2151251762A5051179447 @default.
• W2151251762 hasAuthorship W2151251762A5075917649 @default.
• W2151251762 hasAuthorship W2151251762A5090309244 @default.
• W2151251762 hasBestOaLocation W21512517621 @default.
• W2151251762 hasConcept C104317684 @default.
• W2151251762 hasConcept C111599444 @default.
• W2151251762 hasConcept C121608353 @default.
• W2151251762 hasConcept C126322002 @default.
• W2151251762 hasConcept C147483822 @default.
• W2151251762 hasConcept C203014093 @default.
• W2151251762 hasConcept C2777701055 @default.
• W2151251762 hasConcept C2781018059 @default.
• W2151251762 hasConcept C29537977 @default.
• W2151251762 hasConcept C34981463 @default.
• W2151251762 hasConcept C502942594 @default.
• W2151251762 hasConcept C55493867 @default.
• W2151251762 hasConcept C71924100 @default.
• W2151251762 hasConcept C86803240 @default.
• W2151251762 hasConcept C8891405 @default.
• W2151251762 hasConcept C96232424 @default.
• W2151251762 hasConceptScore W2151251762C104317684 @default.
• W2151251762 hasConceptScore W2151251762C111599444 @default.
• W2151251762 hasConceptScore W2151251762C121608353 @default.
• W2151251762 hasConceptScore W2151251762C126322002 @default.
• W2151251762 hasConceptScore W2151251762C147483822 @default.
• W2151251762 hasConceptScore W2151251762C203014093 @default.
• W2151251762 hasConceptScore W2151251762C2777701055 @default.
• W2151251762 hasConceptScore W2151251762C2781018059 @default.
• W2151251762 hasConceptScore W2151251762C29537977 @default.
• W2151251762 hasConceptScore W2151251762C34981463 @default.
• W2151251762 hasConceptScore W2151251762C502942594 @default.
• W2151251762 hasConceptScore W2151251762C55493867 @default.
• W2151251762 hasConceptScore W2151251762C71924100 @default.
• W2151251762 hasConceptScore W2151251762C86803240 @default.
• W2151251762 hasConceptScore W2151251762C8891405 @default.
• W2151251762 hasConceptScore W2151251762C96232424 @default.
• W2151251762 hasLocation W21512517621 @default.
• W2151251762 hasLocation W21512517622 @default.
• W2151251762 hasOpenAccess W2151251762 @default.
• W2151251762 hasPrimaryLocation W21512517621 @default.
• W2151251762 hasRelatedWork W1217682272 @default.
• W2151251762 hasRelatedWork W2001055320 @default.
• W2151251762 hasRelatedWork W2031356189 @default.
• W2151251762 hasRelatedWork W2043345900 @default.
• W2151251762 hasRelatedWork W2220102944 @default.
• W2151251762 hasRelatedWork W2409441623 @default.
• W2151251762 hasRelatedWork W2792929645 @default.
• W2151251762 hasRelatedWork W2921652900 @default.
• W2151251762 hasRelatedWork W3113198240 @default.
• W2151251762 hasRelatedWork W4291367166 @default.
• W2151251762 isParatext "false" @default.
• W2151251762 isRetracted "false" @default.
• W2151251762 magId "2151251762" @default.
• W2151251762 workType "article" @default.